These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 27587202)
21. A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines. Shahsavar F; Bozorgmehr M; Mirzadegan E; Abedi A; Lighvan ZM; Mohammadi F; Safari N; Amani V; Zarnani AH Anticancer Agents Med Chem; 2016; 16(3):393-403. PubMed ID: 26899296 [TBL] [Abstract][Full Text] [Related]
22. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. McKeage MJ Expert Opin Investig Drugs; 2005 Aug; 14(8):1033-46. PubMed ID: 16050795 [TBL] [Abstract][Full Text] [Related]
23. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617 [TBL] [Abstract][Full Text] [Related]
24. cis-[PtCl2(4,7-H-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine)2]: a sterically restrictive new cisplatin analogue. Reaction kinetics with model nucleobases, DNA interaction studies, antitumor activity, and structure-activity relationships. Navarro JA; Salas JM; Romero MA; Vilaplana R; Gonzalez-Vílchez F; Faure R J Med Chem; 1998 Jan; 41(3):332-8. PubMed ID: 9464364 [TBL] [Abstract][Full Text] [Related]
25. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting. Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961 [TBL] [Abstract][Full Text] [Related]
26. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex. Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702 [TBL] [Abstract][Full Text] [Related]
27. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366 [TBL] [Abstract][Full Text] [Related]
28. The thermodynamics of translesion DNA synthesis past major adducts of enantiomeric analogues of antitumor cisplatin. Malina J; Novakova O; Natile G; Brabec V Chem Asian J; 2012 May; 7(5):1026-31. PubMed ID: 22374916 [TBL] [Abstract][Full Text] [Related]
29. The role of DNA repair pathways in cisplatin resistant lung cancer. O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603 [TBL] [Abstract][Full Text] [Related]
30. Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer Jiang M; Yang T; Chu Y; Zhang Z; Sun H; Liang H; Yang F Dalton Trans; 2022 Mar; 51(13):5257-5270. PubMed ID: 35285843 [TBL] [Abstract][Full Text] [Related]
31. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
32. Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure. Espina M; Corte-Rodríguez M; Aguado L; Montes-Bayón M; Sierra MI; Martínez-Camblor P; Blanco-González E; Sierra LM Metallomics; 2017 May; 9(5):564-574. PubMed ID: 28425536 [TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355 [TBL] [Abstract][Full Text] [Related]
34. Plasmodium falciparum: DNA sequence specificity of cisplatin and cisplatin analogues. Murray V; Campbell HM; Gero AM Exp Parasitol; 2011 Aug; 128(4):396-400. PubMed ID: 21616072 [TBL] [Abstract][Full Text] [Related]
35. NMR studies of models having the Pt(d(GpG)) 17-membered macrocyclic ring formed in DNA by platinum anticancer drugs: Pt complexes with bulky chiral diamine ligands. Saad JS; Benedetti M; Natile G; Marzilli LG Inorg Chem; 2011 May; 50(10):4559-71. PubMed ID: 21510625 [TBL] [Abstract][Full Text] [Related]
36. An investigation of the sequence-specific interaction of cis-diamminedichloroplatinum(II) and four analogues, including two acridine-tethered complexes, with DNA inside human cells. Murray V; Motyka H; England PR; Wickham G; Lee HH; Denny WA; McFadyen WD Biochemistry; 1992 Dec; 31(47):11812-7. PubMed ID: 1445914 [TBL] [Abstract][Full Text] [Related]
37. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Holford J; Raynaud F; Murrer BA; Grimaldi K; Hartley JA; Abrams M; Kelland LR Anticancer Drug Des; 1998 Jan; 13(1):1-18. PubMed ID: 9474239 [TBL] [Abstract][Full Text] [Related]
38. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents. Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Liedert B; Materna V; Schadendorf D; Thomale J; Lage H J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578 [TBL] [Abstract][Full Text] [Related]
40. Analysis of cytotoxicities of platinum compounds. Goodisman J; Hagrman D; Tacka KA; Souid AK Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]